Regeneron Pharmaceuticals Inc. buy Subdi
Summary
This prediction ended on 08.02.17 with a price of €318.51. The prediction for Regeneron Pharmaceuticals Inc. disappointed with a performance of -18.14%. Subdi has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Regeneron Pharmaceuticals Inc. | 2.077% | 2.077% | 55.094% | 98.878% |
iShares Core DAX® | 0.559% | 3.148% | 14.852% | 16.725% |
iShares Nasdaq 100 | -0.854% | 1.869% | 35.463% | 51.117% |
iShares Nikkei 225® | 1.291% | 4.293% | 14.965% | 10.659% |
iShares S&P 500 | 0.492% | 1.945% | 30.310% | 45.443% |
Comments by Subdi for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Subdi stimmt der Buy-Einschätzung von piccolo90 zu
Biotech sollte nach dem Einbruch jetzt wieder gut laufen. Regeneron ist eine Gewinnmaschine mit guten Zukunftsaussichten.
http://www.godmode-trader.de/analyse/regeneron-setzt-zum-grossen-sprung-an,4808178
Subdi stimmt am 02.08.2016 der Buy-Einschätzung von piccolo90 mit dem Kursziel 525,24$ zu.
Überschrift: piccolo90 stimmt dem Sentiment von 'Buy' zu